Last Close
Feb 25  •  04:00PM ET
67.63
Dollar change
+0.55
Percentage change
0.82
%
Index- P/E11.25 EPS (ttm)6.01 Insider Own4.44% Shs Outstand102.00M Perf Week2.22%
Market Cap6.89B Forward P/E9.87 EPS next Y6.86 Insider Trans1.17% Shs Float97.37M Perf Month4.29%
Enterprise Value- PEG1.29 EPS next Q1.03 Inst Own91.44% Short Float3.32% Perf Quarter4.72%
Income621.80M P/S0.92 EPS this Y4.12% Inst Trans0.99% Short Ratio3.68 Perf Half Y1.90%
Sales7.45B P/B1.25 EPS next Y9.72% ROA3.99% Short Interest3.23M Perf YTD10.07%
Book/sh53.92 P/C- EPS next 5Y7.67% ROE11.95% 52W High68.75 -1.63% Perf Year3.73%
Cash/sh- P/FCF9.04 EPS past 3/5Y34.74% -0.54% ROIC8.66% 52W Low53.09 27.39% Perf 3Y19.68%
Dividend Est.2.22 (3.28%) EV/EBITDA- Sales past 3/5Y-0.66% 1.01% Gross Margin- Volatility2.90% 2.77% Perf 5Y28.23%
Dividend TTM2.18 (3.22%) EV/Sales- EPS Y/Y TTM379.80% Oper. Margin13.19% ATR (14)1.96 Perf 10Y78.73%
Dividend Ex-DateMar 09, 2026 Quick Ratio- Sales Y/Y TTM26.71% Profit Margin8.34% RSI (14)58.50 Recom2.00
Dividend Gr. 3/5Y1.91% 4.14% Current Ratio1.03 EPS Q/Q195.52% SMA202.58% Beta1.28 Target Price79.40
Payout36.36% Debt/Eq0.32 Sales Q/Q21.64% SMA506.15% Rel Volume1.02 Prev Close67.08
Employees19102 LT Debt/Eq0.31 EarningsFeb 11 AMC SMA2008.59% Avg Volume878.45K Price67.63
IPOMay 24, 2010 Option/ShortYes / Yes EPS/Sales Surpr.48.12% 13.77% Trades Volume898,675 Change0.82%
Date Action Analyst Rating Change Price Target Change
Nov-14-25Resumed Stephens Equal-Weight
Apr-08-25Upgrade Keefe Bruyette Mkt Perform → Outperform $75
Dec-10-24Downgrade Keefe Bruyette Outperform → Mkt Perform $80
Mar-21-24Upgrade Keefe Bruyette Mkt Perform → Outperform $66 → $69
Jan-10-24Initiated Deutsche Bank Buy
Nov-15-23Initiated Barclays Equal Weight $53
Jul-18-23Resumed BTIG Research Neutral
Feb-10-23Upgrade Stephens Equal-Weight → Overweight $65 → $72
Dec-15-22Downgrade Keefe Bruyette Outperform → Mkt Perform $61
Apr-01-22Downgrade Credit Suisse Outperform → Neutral $97 → $74
Today 12:32AM
Feb-24-26 09:45AM
Feb-19-26 09:00AM
Feb-18-26 10:44AM
09:40AM
12:36AM Loading…
12:36AM
Feb-13-26 11:45AM
Feb-12-26 06:00PM
05:19PM
12:10PM
11:24AM
08:30AM
Feb-11-26 08:30PM
05:55PM
05:05PM
04:44PM Loading…
04:44PM
04:15PM
Feb-10-26 05:10PM
Feb-09-26 10:03PM
Feb-05-26 04:15PM
Feb-04-26 12:34PM
10:03AM
10:00AM
Feb-03-26 11:06PM
06:00PM
Feb-02-26 09:00AM
Jan-29-26 09:40AM
Jan-28-26 06:00PM
Jan-27-26 12:33PM
Jan-24-26 06:47AM
04:30PM Loading…
Jan-21-26 04:30PM
09:50AM
Jan-20-26 09:00AM
Jan-15-26 04:15PM
Jan-14-26 12:10PM
Jan-06-26 10:05AM
Jan-03-26 01:02AM
Jan-01-26 10:35PM
Dec-22-25 09:09AM
Dec-19-25 09:40AM
08:21AM
Dec-18-25 09:00AM
Dec-17-25 09:10AM
Dec-09-25 09:00AM
Dec-03-25 09:40AM
Dec-02-25 01:01PM
09:50AM
Nov-28-25 11:30AM
Nov-21-25 02:41PM
11:30AM
Nov-20-25 09:01AM
Nov-18-25 09:00AM
09:00AM
Nov-17-25 09:41AM
Nov-14-25 07:44AM
Nov-11-25 09:46PM
09:00AM
Nov-06-25 01:47PM
09:00AM
Nov-04-25 04:55PM
04:15PM
09:50AM
09:35AM
09:30AM
Nov-03-25 01:00PM
Oct-29-25 01:06PM
01:37AM
Oct-28-25 09:40AM
Oct-24-25 12:40AM
Oct-23-25 05:06PM
02:01PM
12:15PM
10:37AM
Oct-22-25 07:30PM
06:03PM
05:45PM
04:47PM
04:15PM
09:25AM
Oct-21-25 09:20AM
Oct-20-25 11:08PM
Oct-16-25 10:00AM
09:00AM
09:00AM
09:00AM
09:00AM
09:00AM
09:00AM
09:00AM
Oct-15-25 10:00AM
Oct-13-25 04:15PM
Oct-10-25 12:02AM
Oct-08-25 09:40AM
Oct-05-25 11:12PM
Sep-29-25 11:45AM
Sep-24-25 01:35PM
01:31PM
Sep-22-25 09:40AM
08:54AM
Sep-19-25 12:05PM
First American Financial Corp. engages in the provision of title insurance and settlement services to the real estate and mortgage industries. It also provides other financial services and risk solutions. It operates through the following segments: Title Insurance and Services, Specialty Insurance, and Corporate. The Title Insurance and Services segment offers title insurance, escrow, closing services and similar or related financial services domestically and internationally in connection with residential and commercial real estate transactions. The Specialty Insurance segment issues property and casualty insurance policies and sells home warranty products. The Corporate segment includes the investment and management of the company's venture investment portfolio. The company was founded in 1889 and is headquartered in Santa Ana, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KENNEDY PARKER SDirectorFeb 17 '26Buy67.8544,8413,042,506251,552Feb 18 08:23 PM
KENNEDY PARKER SDirectorFeb 13 '26Buy67.1715,0001,007,595206,711Feb 18 08:23 PM
DOTI JAMES LDirectorAug 28 '25Sale65.177,692501,29869,091Aug 29 06:17 PM
DOTI JAMES LDirectorAug 28 '25Proposed Sale65.177,692501,298Aug 28 02:30 PM
McCarthy Margaret MDirectorAug 13 '25Sale65.633,500229,70528,095Aug 14 05:11 PM
McCarthy Margaret MDirectorAug 13 '25Proposed Sale65.633,500229,705Aug 13 03:02 PM
DEGIORGIO KENNETH DFormer Officer, DirectorApr 24 '25Proposed Sale62.79250,66915,739,391Apr 24 03:34 PM
Last Close
Feb 25  •  04:00PM ET
38.16
Dollar change
-0.43
Percentage change
-1.11
%
NVO Novo Nordisk ADR daily Stock Chart
Index- P/E11.00 EPS (ttm)3.47 Insider Own0.01% Shs Outstand3.37B Perf Week-22.49%
Market Cap128.57B Forward P/E11.21 EPS next Y3.40 Insider Trans0.00% Shs Float3.37B Perf Month-40.36%
Enterprise Value144.92B PEG14.56 EPS next Q0.81 Inst Own9.44% Short Float0.94% Perf Quarter-19.88%
Income15.45B P/S2.75 EPS this Y-7.92% Inst Trans-0.10% Short Ratio1.43 Perf Half Y-32.27%
Sales46.77B P/B5.56 EPS next Y1.57% ROA20.59% Short Interest31.69M Perf YTD-25.00%
Book/sh6.87 P/C30.33 EPS next 5Y0.77% ROE61.25% 52W High93.80 -59.32% Perf Year-58.04%
Cash/sh1.26 P/FCF14.36 EPS past 3/5Y26.28% 20.36% ROIC31.38% 52W Low38.36 -0.52% Perf 3Y-46.10%
Dividend Est.1.68 (4.39%) EV/EBITDA6.41 Sales past 3/5Y23.19% 19.21% Gross Margin80.90% Volatility2.12% 3.47% Perf 5Y5.50%
Dividend TTM1.73 (4.53%) EV/Sales3.10 EPS Y/Y TTM5.57% Oper. Margin41.17% ATR (14)2.36 Perf 10Y46.71%
Dividend Ex-DateMar 30, 2026 Quick Ratio0.57 Sales Y/Y TTM11.11% Profit Margin33.03% RSI (14)24.70 Recom2.47
Dividend Gr. 3/5Y28.28% 20.66% Current Ratio0.80 EPS Q/Q3.95% SMA20-22.37% Beta0.72 Target Price53.01
Payout38.07% Debt/Eq0.67 Sales Q/Q0.66% SMA50-27.73% Rel Volume2.48 Prev Close38.59
Employees68794 LT Debt/Eq0.61 EarningsFeb 04 BMO SMA200-33.58% Avg Volume22.14M Price38.16
IPOApr 30, 1981 Option/ShortYes / Yes EPS/Sales Surpr.3.40% 3.10% Trades Volume54,889,723 Change-1.11%
Date Action Analyst Rating Change Price Target Change
Feb-24-26Downgrade Kepler Buy → Hold
Feb-24-26Downgrade JP Morgan Overweight → Neutral
Feb-23-26Downgrade Deutsche Bank Buy → Hold
Feb-12-26Upgrade Jefferies Underperform → Hold
Jan-27-26Initiated Citigroup Neutral
Dec-08-25Downgrade Argus Buy → Hold
Oct-27-25Resumed Jefferies Underperform
Oct-01-25Upgrade HSBC Securities Hold → Buy
Sep-29-25Downgrade Morgan Stanley Equal-Weight → Underweight $47
Sep-17-25Upgrade Berenberg Hold → Buy
Today 03:36PM
01:42PM
01:01PM
12:47PM
11:33AM
11:00AM Loading…
11:00AM
10:41AM
09:28AM
09:13AM
08:53AM
08:40AM
08:01AM
07:08AM
04:14AM
03:00AM
05:18PM Loading…
Feb-24-26 05:18PM
04:35PM
03:35PM
03:32PM
02:48PM
02:47PM
02:19PM
01:31PM
12:03PM
12:00PM
11:31AM
10:43AM
10:24AM
10:09AM
10:08AM
09:58AM Loading…
09:58AM
09:55AM
09:18AM
09:15AM
09:14AM
09:02AM
08:13AM
08:01AM
07:53AM
07:51AM
07:48AM
07:22AM
06:40AM
06:00AM
05:22AM
05:19AM
04:12AM
Feb-23-26 08:18PM
06:49PM
05:33PM
05:17PM
04:40PM
04:27PM
04:25PM
04:11PM
03:32PM
03:20PM
03:13PM
02:30PM
02:29PM
02:03PM
01:50PM
01:10PM
01:01PM
12:57PM
12:44PM
12:34PM
11:55AM
11:44AM
11:42AM
11:35AM
11:32AM
11:15AM
11:10AM
11:08AM
10:35AM
10:33AM
09:56AM
09:53AM
09:41AM
09:36AM
09:30AM
09:11AM
09:03AM
09:00AM
08:46AM
08:41AM
08:11AM
08:09AM
07:39AM
07:04AM
06:32AM
05:58AM
05:33AM
05:31AM
05:07AM
03:19AM
Feb-22-26 02:00PM
05:03AM
Feb-21-26 10:03AM
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Nordisk A/S10% OwnerMay 30 '25Proposed Sale2.14921,8971,972,859May 30 08:31 AM